Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by covalently binding to the (H+, K+)-ATPase enzyme system at the secretory surface of the gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. The binding to the (H+, K+)-ATPase results in a duration of antisecretory effect that persists longer than 24 hours for all doses tested (20 mg to 120 mg)
Pantoprazole is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production. Pantoprazole is unstable in acid and is administered orally in the form of an enteric-coated tablet Pantoprazole is completely and rapidly absorbed after oral administration. The absolute bioavailability from the tablet was found to be about 77 %. Pantoprazole is extensively metabolized in the liver through the cytochrome P450 (CYP) system. Renal elimination represents the major route of excretion (about 80%) for the metabolites of Pantoprazole; the rest is excreted with the faeces.
Domperidone acts as a gastrointestinal emptying (delayed) adjunct and peristaltic stimulant. The gastroprokinetic properties of Domperidone are related to its peripheral dopamine receptor blocking properties.. In fasting subjects, Domperidone is rapidly absorbed after oral administration. Domperidone is 91-93% bound to plasma proteins. Domperidone undergoes rapid and extensive hepatic metabolism and Urinary and faecal excretions amount to 31 and 66% of the oral dose respectively